Manganese Catalyst Chemoselective Methylene Hydroxylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current catalyst systems fail to achieve chemoselective oxidation of strong aliphatic methylene C—H bonds in the presence of oxidatively labile aromatic functionalities, which is crucial for late-stage derivatizations of pharmaceuticals and natural products.
Innovation Solution
A manganese complex, Mn(CF3-PDP), is developed, which, in combination with chloroacetic acid, enables high chemoselectivity and reactivity for oxidizing aliphatic methylene C—H bonds even in the presence of medicinally important aromatic moieties, bypassing the need for directing groups or molecular recognition elements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If a catalyst system is designed to oxidize strong aliphatic methylene C-H bonds, then reactivity is improved, but chemoselectivity deteriorates due to oxidation of aromatic functionalities
Solution Approach 1:
The patent changes the oxidation potential parameter of the catalyst system by switching from iron to manganese metal center, which has a lower oxidation potential. This allows the catalyst to selectively oxidize methylene C-H bonds while leaving aromatic functionalities intact, resolving the contradiction between reactivity and chemoselectivity
Solution Approach 2:
The patent introduces a carboxylic acid additive that locally modifies the catalyst's interaction with the substrate. The acid coordinates to the manganese center, creating a specific local environment that enhances chemoselectivity for methylene oxidation while protecting aromatic groups from oxidation
2Manufacturing precision
If a catalyst is designed for high chemoselectivity by reducing oxidation capacity, then chemoselectivity is improved, but reactivity deteriorates
Solution Approach 1:
The patent creates a composite catalytic system combining manganese metal center with carboxylic acid ligands. This composite structure achieves both high chemoselectivity through the acid-modified catalyst and maintains high reactivity, overcoming the limitation of reduced oxidation capacity
3Manufacturing precision
If iron enzymes are used for methylene hydroxylation, then chemoselectivity is improved through restricted substrate access, but ease of operation deteriorates due to difficulty in preparative scale use
Solution Approach 1:
The patent creates a small molecule copy of the iron enzyme's active site using manganese complex with carboxylic acid ligands. This synthetic catalyst replicates the chemoselectivity of enzymatic systems while being much easier to handle and scale up for preparative applications
Solution Approach 2:
The patent replaces complex, expensive, and difficult-to-handle iron enzymes with a simple, inexpensive manganese complex that can be easily prepared and used on preparative scales, sacrificing the biological complexity for practical ease of use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for preparative remote methylene oxidation in 50 aromatic compounds, including drug scaffolds, with unprecedented chemoselectivity and reactivity, facilitating the rapid diversification of aromatic drugs and identification of their metabolites.
Implementation Method 1
A chemoselective and reactive manganese catalyst that enables the strategic advantages of late-stage aliphatic C—H hydroxylation
Implementation Method 2
enables high chemoselectivity and reactivity for oxidizing aliphatic methylene C—H bonds
Data Source
AI summary
A chemoselective and reactive Mn(CF3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.